A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis

• Published in: Journal of the American Academy of Dermatology Vol. 80; no. 1; pp. 89 - 98.e3
• Main Authors: Peppers, Johnny, Paller, Amy S., Maeda-Chubachi, Tomoko, Wu, Sterling, Robbins, Kevin, Gallagher, Kelly, Kraus, John E.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2019
• Subjects: Adolescent; Adult; Aged; atopic dermatitis; Child; Dermatitis, Atopic - drug therapy; Double-Blind Method; Female; GSK2894512; Humans; Male; Middle Aged; Resorcinols - therapeutic use; Skin Cream; Stilbenes - therapeutic use; tapinarof; therapeutic aryl hydrocarbon receptor modulating agent; Young Adult; IGA; AE; NRI; tapinarof; CI; atopic dermatitis; EASI75; AhR; NRS; therapeutic aryl hydrocarbon receptor modulating agent; BSA; EASI; TEAE; GSK2894512

Safe and efficacious topical treatments are needed for atopic dermatitis (AD). We assessed the safety and efficacy of tapinarof cream (2 concentrations and 2 application frequencies) in patients with AD. A double-blind, vehicle-controlled, randomized, 6-arm trial (1:1:1:1:1:1) in patients age 12 to...